Introduction: Sunitinib has shown significant improvement of progression-free survival in patients with advanced pancreatic neuroendocrine tumors (pNET).
Aim(s): Assessment of efficacy, safety and tolerability in clinical practice.
Materials and methods: Patients with advanced, differentiated (G1, G2) pNET treated with sunitinib between 2011 and 2012 in Essen and Marburg, Germany, were evaluated in terms of response to therapy, side effects and dose adjustments. All patients had progressive disease when starting sunitinib. Twenty-one patients (six males), median age 64 years (range 28-78) were included in the study.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Harald Lahner
To read results and conclusion, please login ...
Further abstracts you may be interested in